, Volume 64, Issue 21, pp 2447–2462 | Cite as

Long-Cycle Treatment with Oral Contraceptives

  • Inka Wiegratz
  • Herbert KuhlEmail author
Review Article


The conventional regimen of oral contraceptive (OC) use mimics the natural cycles by causing regular withdrawal bleeding, which can be avoided by omission of the hormone-free interval of 7 days. Consequently, long-cycle regimens with continuous administration of OCs for 3 or 6 months followed by a hormone-free interval of 7 days may reduce the frequency of menstruations and cycle-dependent complaints. Surveys have revealed that, despite a higher rate of irregular bleeding, the majority of women prefer the long-cycle regimen to the conventional OC regimen with regular bleeds every 4 weeks because it may improve quality of life.

As this regimen increases the contraceptive efficacy to a large degree, continuous treatment with OCs may prevent unintended pregnancies in women who miss a pill or are concomitantly treated with drugs that are able to impair the efficacy of OCs. Postponement of withdrawal bleeding may also reduce or prevent menses-associated disorders such as hypermenorrhoea and dysmenorrhoea, and have beneficial effects in patients with haemorrhagic diathesis, endometriosis, uterine leiomyoma and polycystic ovary syndrome. Continuous use of OCs prevents the cyclic fluctuations of serum levels of ethinylestradiol and progestogen and, hence, the cyclic variations of metabolic serum parameters.

Although the long-cycle regimen is initially associated with an elevated rate of irregular bleeding, the total number of bleeding days that require sanitary product protection is lower than during conventional OC treatment. Many physicians tend to prescribe extended OC cycles for postponement of menstruation or reduction of frequency of regular bleeding.

This review summarises and examines the available data on OC long-cycle regimens. The data suggest that the rate of treatment-related side effects with OCs according to the long-cycle regimen is similar to that of conventional OC regimens. However, clinical trials are necessary to assess the impact of long-term OC long cycles on safety, particularly the risk of cancer and cardiovascular disease, and fertility after discontinuation of treatment.


Endometriosis Oral Contraceptive Unintended Pregnancy Ethinylestradiol Dienogest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Wilbush J. La menopausie: the birth of a syndrome. Maturitas 1979; 1: 145–51PubMedCrossRefGoogle Scholar
  2. 2.
    Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 2000; 355: 922–4PubMedCrossRefGoogle Scholar
  3. 3.
    Sulak P, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6PubMedCrossRefGoogle Scholar
  4. 4.
    Shakespeare J, Neve E, Hodder E. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291PubMedCrossRefGoogle Scholar
  5. 5.
    den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357–62CrossRefGoogle Scholar
  6. 6.
    Rutter W, Knight C, Vizzard J, et al. Women’s attitude to withdrawal bleeding and their knowledge and beliefs about the oral contraceptive pills. Med J Aust 1988; 149: 417–9PubMedGoogle Scholar
  7. 7.
    Glasier AF, Smith KB, van der Spuy ZM, et al. Amenorrhea associated with contraception: an international study on acceptability. Contraception 2003; 67: 1–8PubMedCrossRefGoogle Scholar
  8. 8.
    Wiegratz I, Hommel HH, Zimmermann T, et al. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69: 37–42PubMedCrossRefGoogle Scholar
  9. 9.
    Sulak PJ, Kuehl TJ, Ortiz M, et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142–9PubMedCrossRefGoogle Scholar
  10. 10.
    Schwartz JL, Creinin MD, Pymar HC. The trimonthly combination oral contraceptive regimen: is it cost effective? Contraception 1999; 60: 263–7PubMedCrossRefGoogle Scholar
  11. 11.
    Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98: 771–8PubMedCrossRefGoogle Scholar
  12. 12.
    Braunstein JB, Hausfeld J, Hausfeld J, et al. Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens. Obstet Gynecol 2003; 102: 699–708PubMedCrossRefGoogle Scholar
  13. 13.
    Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol 2002; 100: 683–7PubMedCrossRefGoogle Scholar
  14. 14.
    Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: S276–9CrossRefGoogle Scholar
  15. 15.
    Guillebaud J. The forgotten pill: and the paramount importance of the pill-free week. Br J Fam Plann 1987; 12 Suppl.: S35–43Google Scholar
  16. 16.
    Wang E, Shi S, Cekan SZ, et al. Hormonal consequences of ‘missing the pill’. Contraception 1982; 26: 545–66PubMedCrossRefGoogle Scholar
  17. 17.
    Fraser IS, Jansen RPS. Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors. Contraception 1983; 27: 531–51PubMedCrossRefGoogle Scholar
  18. 18.
    Kuhl H, Gahn G, Romberg G, et al. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters. 1: effects on sexual hormone levels. Contraception 1985; 31: 583–93Google Scholar
  19. 19.
    Molloy BG, Coulson KA, Lee JM, et al. ‘Missed pill’ conception: fact or fiction? BMJ 1985; 290: 1474–5PubMedCrossRefGoogle Scholar
  20. 20.
    Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel upon various hormonal parameters. Contraception 1998; 38: 593–603CrossRefGoogle Scholar
  21. 21.
    Killick SR, Bancroft K, Oelbaum S, et al. Extending the duration of the pill-free interval during combined oral contraception. Adv Contracept 1990; 6: 33–40PubMedCrossRefGoogle Scholar
  22. 22.
    Aden U, Jung-Hoffmann C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception 1998; 58: 75–81PubMedCrossRefGoogle Scholar
  23. 23.
    Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet Gynecol 1989; 161: 1159–62PubMedGoogle Scholar
  24. 24.
    Killick SR. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. Fertil Steril 1989; 52: 580–2PubMedGoogle Scholar
  25. 25.
    Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993; 47: 583–90PubMedCrossRefGoogle Scholar
  26. 26.
    Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54: 71–7PubMedCrossRefGoogle Scholar
  27. 27.
    Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril 1999; 72: 115–20PubMedCrossRefGoogle Scholar
  28. 28.
    Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive: the Seasonale-301 Study Group. Contraception 2003; 68: 89–96PubMedCrossRefGoogle Scholar
  29. 29.
    Loudon NB, Foxwell M, Potts DM, et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cyclic pill regimen. BMJ 1977; 2: 487–90PubMedCrossRefGoogle Scholar
  30. 30.
    Hamerlynck JVTH, Vollebregt JA, Doornebos CM, et al. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives. Contraception 1987; 35: 199–205PubMedCrossRefGoogle Scholar
  31. 31.
    de Voogt WS. Postponement of withdrawal bleeding with a monophasic oral contraceptive containing desogestrel and ethinylestradiol. Contraception 1991; 44: 107–12CrossRefGoogle Scholar
  32. 32.
    Kornaat H, Geerdink MH, Klitsie JW. The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet). Contraception 1992; 45: 121–7CrossRefGoogle Scholar
  33. 33.
    Cachrimanidou A-C, Hellberg D, Nilsson S, et al. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993; 48: 205–16PubMedCrossRefGoogle Scholar
  34. 34.
    Cachrimanidou A-C, Hellberg D, Nilsson S, et al. Hemostasis profile and lipid metabolism with long interval use of a desogestrel-containing oral contraceptive. Contraception 1994; 50: 153–65PubMedCrossRefGoogle Scholar
  35. 35.
    Kovacs GT, Rusden J, Evans A. A trimonthly regimen for oral contraceptives. Br J Fam Plann 1994; 19: 274–5Google Scholar
  36. 36.
    Coutinho EM, O’Dwyer E, Barbosa IC, et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception 1995; 51: 355–8PubMedCrossRefGoogle Scholar
  37. 37.
    Ruchhoft E, Elkind-Hirsch KE, Malinak R. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertil Steril 1996; 66: 54–60PubMedGoogle Scholar
  38. 38.
    Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179–83PubMedCrossRefGoogle Scholar
  39. 39.
    Vercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52–61PubMedCrossRefGoogle Scholar
  40. 40.
    Kwiecin M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003; 67: 9–13CrossRefGoogle Scholar
  41. 41.
    Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653–61PubMedCrossRefGoogle Scholar
  42. 42.
    Back DJ, Breckenridge AM, Crawford F, et al. Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs 1981; 21: 46–61PubMedCrossRefGoogle Scholar
  43. 43.
    D’Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986; 20: 353–62PubMedGoogle Scholar
  44. 44.
    Back DJ, Grimmer SFM, Orme MLE, et al. Evaluation of committee on safety of medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527–32PubMedCrossRefGoogle Scholar
  45. 45.
    Back DJ, Orme MLE. Pharmacokinetic drag interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472–84PubMedCrossRefGoogle Scholar
  46. 46.
    Diamond MP, Greene JW, Thompson JM, et al. Interactions of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 1985; 31: 623–32PubMedCrossRefGoogle Scholar
  47. 47.
    Jung-Hoffmann C, Kuhl H. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism. Am J Obstet Gynecol 1990; 163: 2183–97Google Scholar
  48. 48.
    Szoka PR, Edgren RA. Drag interactions with oral contraceptives: compilation and analysis of an adverse experience report database. Fertil Steril 1988; 49 (5 Suppl. 2): 31–8Google Scholar
  49. 49.
    Park BK, Kitteringham NR, Pirmohamed M, et al. Relevance of induction of human drag-metabolizing enzymes: pharmacological and toxicological implications. Br J Pharmacol 1996; 41: 477–91Google Scholar
  50. 50.
    Birkhäuser M, Braendle W, Breckwoldt M, et al. 24th Workshop of the ‘Zürcher Gesprächskreis’ May 2000: recommendations on oral contraception. Frauenarzt 2000; 41: 1053–8Google Scholar
  51. 51.
    Zeitoun K, Takayama K, Sasano H, et al. Deficient 17β-hydrxysteroid dehydrogenase type 2 expression in endometriosis: failure to metablize 17β-estradiol. J Clin Endocrinol Metab 1998; 83: 4474–80PubMedCrossRefGoogle Scholar
  52. 52.
    Brosens IA, Pijnenborg R. Comparative study of the estrogenic effect of ethinylestradiol and mestranol on the endometrium. Contraception 1976; 14: 679–85PubMedCrossRefGoogle Scholar
  53. 53.
    Parazzini F, Ferraroni M, Bocciolone L, et al. Contraceptive methods and risk of pelvic endometriosis. Contraception 1994; 49: 47–55PubMedCrossRefGoogle Scholar
  54. 54.
    Pickersgill A. GnRH agonists and add-back therapy: is there a perfect combination? Br J Obstet Gynaecol 1998; 105: 475–85PubMedCrossRefGoogle Scholar
  55. 55.
    Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70: 432–9PubMedCrossRefGoogle Scholar
  56. 56.
    Friedman AJ, Thomas PP. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol 1995; 85: 631–5PubMedCrossRefGoogle Scholar
  57. 57.
    Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2003; 83: 149–55CrossRefGoogle Scholar
  58. 58.
    Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. Controversies in endocrinology: a modem medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003; 88: 1927–32PubMedCrossRefGoogle Scholar
  59. 59.
    Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302–12PubMedCrossRefGoogle Scholar
  60. 60.
    Rizk DEE, Kumar RM. Congenital afibrinogenemia: treatment of excessive menstrual bleeding with continuous oral contraceptive. Am J Hematol 1996; 52: 237–8PubMedCrossRefGoogle Scholar
  61. 61.
    Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18–30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77: 13–9PubMedCrossRefGoogle Scholar
  62. 62.
    Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol 1996; 175: 787–92PubMedCrossRefGoogle Scholar
  63. 63.
    Sveindottir H, Bäckström T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79: 405–13PubMedCrossRefGoogle Scholar
  64. 64.
    Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70: 229–40PubMedCrossRefGoogle Scholar
  65. 65.
    Mattson RH, Rebar RW. Contraceptive methods for women with neurologic disorders. Am J Obstet Gynecol 1993; 168: 2027–32PubMedGoogle Scholar
  66. 66.
    Dennerstein L, Morse C, Burrows G, et al. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988; 2: 113–20PubMedCrossRefGoogle Scholar
  67. 67.
    Lichten EM, Lichten JB, Whitty A. The confirmation of a biochemical marker for women’s hormonal migraine: the depo-estradiol challenge test. Headache 1996; 36: 367–71PubMedCrossRefGoogle Scholar
  68. 68.
    Sulak PJ. Creative use of oral contraceptives in the perimenopausal patient. In: Santoro N, Goldstein SR, editors. Textbook of perimenopausal gynecology. New York: Parthenon, 2003: 99–107Google Scholar
  69. 69.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–27CrossRefGoogle Scholar
  70. 70.
    Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025–32PubMedCrossRefGoogle Scholar
  71. 71.
    Stanford JL, Brinton LA, Berman ML, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 1993; 54: 243–8PubMedCrossRefGoogle Scholar
  72. 72.
    Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7PubMedCrossRefGoogle Scholar
  73. 73.
    Farrow A, Hull MGR, Northstone K, et al. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod 2002; 10: 2754–61CrossRefGoogle Scholar
  74. 74.
    The European Medicines Agency (Committee for Medicinal Products for Human Use [CHMP]). Note for guidance on clinical investigation of steroid contraceptives in women [draft]. London: EMEA, 2004 Jun 23Google Scholar
  75. 75.
    Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of strogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003; 289: 3243–53PubMedCrossRefGoogle Scholar
  76. 76.
    The Women’s Health Initiative Steering Committee. Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701–12CrossRefGoogle Scholar
  77. 77.
    Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498–508PubMedCrossRefGoogle Scholar
  78. 78.
    Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559–65PubMedCrossRefGoogle Scholar
  79. 79.
    Cline JM, Soderqvist G, von Schoultz E, et al. Effect of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174: 93–100PubMedCrossRefGoogle Scholar
  80. 80.
    Suparto IH, Williams JK, Cline JM, et al. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammari gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol 2003; 188: 1132–40PubMedCrossRefGoogle Scholar
  81. 81.
    Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27CrossRefGoogle Scholar
  82. 82.
    Brinton LA, Vessey MP, Flavel R, et al. Risk factors for benign breast disease. Am J Epidemiol 1981; 113: 203–14PubMedGoogle Scholar
  83. 83.
    Bloemenkamp KWM, Rosendaal FR, Biiller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999; 159: 65–70PubMedCrossRefGoogle Scholar
  84. 84.
    Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160: 49–52PubMedCrossRefGoogle Scholar
  85. 85.
    Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thrombos Haemost 1997; 78: 1–6Google Scholar
  86. 86.
    Duffy TJ, Ray R. Oral contraceptive use: prospective follow-up of women with suspected glucose intolerance. Contraception 1984; 40: 197–208CrossRefGoogle Scholar
  87. 87.
    Jung-Hoffmann C, Kuhl H. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception 1990; 42: 423–8PubMedCrossRefGoogle Scholar
  88. 88.
    Kuhl H, Jung-Hoffmann C, Storch A, et al. New aspects on the mechanism of action of contraceptive steroids: recent pharmacokinetic studies of low dose formulations. Adv Contraception 1991; 7 Suppl. 3: 149–63Google Scholar
  89. 89.
    Kuhl H, Jung-Hoffmann C, Heidt F. Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel. Contraception 1988; 38: 381–90PubMedCrossRefGoogle Scholar
  90. 90.
    März W, Jung-Hoffmann C, Heidt F, et al. Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel. Contraception 1990; 41: 245–58PubMedCrossRefGoogle Scholar
  91. 91.
    Jung-Hoffmann C, Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestins contained in oral contraceptives. Contraception 1989; 40: 299–312PubMedCrossRefGoogle Scholar
  92. 92.
    Clarke AK, Miller SJ. The debate regarding continuous use of oral contraceptives. Ann Pharmacotherapy 2001; 35: 1480–4CrossRefGoogle Scholar

Copyright information

© Adis data information BV 2004

Authors and Affiliations

  1. 1.Center of Gynecology and ObstetricsUniversity Hospital of FrankfurtFrankfurt am MainGermany

Personalised recommendations